Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-20T02:25:42.634Z Has data issue: false hasContentIssue false
  • English
  • Français

Schizophrenia: an ever-changing entity

Published online by Cambridge University Press:  14 July 2015

B. Browne
B. Browne*
Affiliation:
Department of Psychiatry, School of Medicine, Trinity College, Dublin
*
*Address for correspondence: B. Browne, 8 Synge St, Portobello, Dublin 8, Ireland (Email: [email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Perspectives
Information
Irish Journal of Psychological Medicine , Volume 33 , Issue 1 , March 2016 , pp. 61 - 64
Copyright
© College of Psychiatrists of Ireland 2015 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Cross-Disorder Group of the Psychiatric Genomics Consortium (2013). Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 381, 1371–1379.Google Scholar
Expert Group on Mental Health Policy, HSE (2006). A Vision for Change (http://www.hse.ie/eng/services/publications/Mentalhealth/Mental_Health_-_A_Vision_for_Change.pdf). Accessed November 2014.Google Scholar
Goldacre, B (2012). Bad Pharma, 1st edn. Fourth Estate: London.Google Scholar
Hamshere, M, Stergiakouli, E, Langley, K, Martin, J, Holmans, P, Kent, L, Owen, MJ, Gill, M, Thapar, A, O’Donovan, M, Craddock, N (2013). Shared polygenic contribution between childhood attention-deficit hyperactivity disorder and adult schizophrenia. British Journal of Psychiatry 203, 107–111.Google Scholar
Howes, OD, Kapur, S (2014). A neurobiological hypothesis for schizophrenia: type A (hyperdopaminergic) and type B (normodopaminergic). British Journal of Psychiatry 205, 1–3.Google Scholar
Laarson, H, Rydén, E, Boman, M, Långström, N, Lichtenstein, P, Landén, M (2013). Risk of bipolar disorder and schizophrenia in relatives of people with attention-deficit hyperactivity disorder. British Journal of Psychiatry 203, 103–106.Google Scholar
McCartney, M (2012). The Patient Paradox. Pinter and Martin: London.Google Scholar
National Institute for Health and Care Excellence (2014). Psychosis and schizophrenia in adults: treatment and management. (CG178) http://www.nice.org.uk/guidance/cg178. Accessed November 2014.Google Scholar
O’Sullivan, BP, Orenstein, DM, Milla, CE (2013). Pricing for Orphan Drugs. Will the Market Bear What Society Cannot? Journal of the American Medical Association 310, 1343–1344.Google Scholar
Vertex Pharmaceuticals Incorporated (2011). Phase 3 STRIVE Study of VX-770 showed durable improvements in lung function (FEV1) and other measures of disease among people with a specific type of cystic fibrosis, press release, Vertex Pharmaceuticals Incorporated, 10 June.Google Scholar
Whitaker, R (2011). Anatomy of an Epidemic: Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America. 1st edition. New York, NY: Crown Publishing Group.Google Scholar